{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:36:45Z","timestamp":1790811405546,"version":"4.1.0"},"reference-count":45,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T00:00:00Z","timestamp":1719705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Inflammatory bowel diseases (IBDs), such as Crohn\u2019s disease (CD) and ulcerative colitis (UC), are chronic diseases of the digestive system with a multifactorial and not fully understood etiology. There is research suggesting that they may be initiated by genetic, immunological, and lifestyle factors. In turn, all of these factors play an important role in the modulation of intestinal microflora, and a significant proportion of IBD patients struggle with intestinal dysbiosis, which leads to the conclusion that intestinal microflora disorders may significantly increase the risk of developing IBD. Additionally, in IBD patients, Toll-like receptors (TLRs) produced by intestinal epithelial cells and dendritic cells treat intestinal bacterial antigens as pathogens, which causes a disruption of the immune response, resulting in the development of an inflammatory process. This may result in the occurrence of intestinal dysbiosis, which IBD patients are significantly vulnerable to. In this study, we reviewed scientific studies (in particular, systematic reviews with meta-analyses, being studies with the highest level of evidence) regarding the microflora of patients with IBD vs. the microflora in healthy people, and the use of various strains in IBD therapy.<\/jats:p>","DOI":"10.3390\/nu16132092","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T04:53:27Z","timestamp":1719809607000},"page":"2092","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Importance of Gut Microbiota in Patients with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"16","author":[{"given":"Natalia","family":"Ekstedt","sequence":"first","affiliation":[{"name":"Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-1823","authenticated-orcid":false,"given":"Dominika","family":"Jamio\u0142-Milc","sequence":"additional","affiliation":[{"name":"Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Pieczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Food Science and Dietetics, Wroclaw Medical University, Borowska 211, 50-556 Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,30]]},"reference":[{"key":"ref_1","unstructured":"Kumar, V., Abbas, A.K., Aster, J.C., Robbins, S.L., and Perkins, J.A. (2018). Robbins Basic Pathology, Elsevier. [10th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/j.sempedsurg.2017.10.003","article-title":"Clinical Presentation of Crohn\u2019s, Ulcerative Colitis, and Indeterminate Colitis: Symptoms, Extraintestinal Manifestations, and Disease Phenotypes","volume":"26","author":"Yu","year":"2017","journal-title":"Semin. Pediatr. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"M\u2019Koma, A.E. (2022). Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina, 58.","DOI":"10.3390\/medicina58050567"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-Analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1462-5822.2007.01108.x","article-title":"Gut Flora, Toll-like Receptors and Nuclear Receptors: A Tripartite Communication That Tunes Innate Immunity in Large Intestine","volume":"10","author":"Lundin","year":"2008","journal-title":"Cell. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Saez-Lara, M.J., Gomez-Llorente, C., Plaza-Diaz, J., and Gil, A. (2015). The Role of Probiotic Lactic Acid Bacteria and Bifidobacteria in the Prevention and Treatment of Inflammatory Bowel Disease and Other Related Diseases: A Systematic Review of Randomized Human Clinical Trials. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/505878"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/intimm\/dxs094","article-title":"Regulation of Intestinal Homeostasis by Innate and Adaptive Immunity","volume":"24","author":"Kayama","year":"2012","journal-title":"Int. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apm.12609","article-title":"The Human Gastrointestinal Tract and Oral Microbiota in Inflammatory Bowel Disease: A State of the Science Review","volume":"125","year":"2017","journal-title":"APMIS Acta Pathol. Microbiol. Immunol. Scand."},{"key":"ref_11","unstructured":"Stachowska, E. (2021). Therapy in Inflammatory Bowel Disease-Use of Special-Purpose Foods. Nutrition in Intestinal Microbiota Disorders, PZWL Wydawnictwo Lekarskie."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1073\/pnas.1116053109","article-title":"Metagenomic Systems Biology of the Human Gut Microbiome Reveals Topological Shifts Associated with Obesity and Inflammatory Bowel Disease","volume":"109","author":"Greenblum","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/00365521.2016.1216587","article-title":"The Association between the Gut Microbiota and the Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis","volume":"51","author":"Prosberg","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhou, Y., and Zhi, F. (2016). Lower Level of Bacteroides in the Gut Microbiota Is Associated with Inflammatory Bowel Disease: A Meta-Analysis. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/5828959"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1206095","article-title":"The Toll-Like Receptor 2 Pathway Establishes Colonization by a Commensal of the Human Microbiota","volume":"332","author":"Round","year":"2011","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/jcp.25911","article-title":"Probiotics Are a Good Choice in Remission of Inflammatory Bowel Diseases: A Meta Analysis and Systematic Review","volume":"233","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.MIB.0000437495.30052.be","article-title":"Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohn\u2019s Disease, and Pouchitis: Meta-Analysis of Randomized Controlled Trials","volume":"20","author":"Shen","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinre.2014.10.008","article-title":"The Interplay between the Intestinal Microbiota and the Immune System","volume":"39","author":"Lei","year":"2015","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Akutko, K., and Stawarski, A. (2021). Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112466"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Biagioli, M., Carino, A., Di Giorgio, C., Marchian\u00f2, S., Bordoni, M., Roselli, R., Distrutti, E., and Fiorucci, S. (2020). Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation. Nutrients, 12.","DOI":"10.3390\/nu12071945"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s00394-021-02503-5","article-title":"Clinical Effects and Gut Microbiota Changes of Using Probiotics, Prebiotics or Synbiotics in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Zhang","year":"2021","journal-title":"Eur. J. Nutr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/apt.13344","article-title":"Systematic Review with Meta-Analysis: Saccharomyces Boulardii in the Prevention of Antibiotic-Associated Diarrhoea","volume":"42","author":"Szajewska","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","first-page":"129","article-title":"Therapeutic Effects of Saccharomyces Boulardii on Mild Residual Symptoms in a Stable Phase of Crohn\u2019s Disease with Special Respect to Chronic Diarrhea\u2014A Pilot Study","volume":"31","author":"Plein","year":"1993","journal-title":"Z. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.3748\/wjg.v16.i18.2202","article-title":"Systematic Review and Meta-Analysis of Saccharomyces Boulardii in Adult Patients","volume":"16","author":"McFarland","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_25","first-page":"5","article-title":"Biologically active peptides from food proteins: In silico, in vitro and in vivo studies, application aspects, and safety evaluation","volume":"5","author":"Minkiewicz","year":"2015","journal-title":"Zywnosc. Nauka Technol. Jakosc\/Food Sci. Technol. Qual."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1111\/1541-4337.12755","article-title":"Probiotics in the Dairy Industry-Advances and Opportunities","volume":"20","author":"Gao","year":"2021","journal-title":"Compr. Rev. Food Sci. Food Saf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.3748\/wjg.v22.i24.5505","article-title":"Role and Mechanisms of Action of Escherichia coli Nissle 1917 in the Maintenance of Remission in Ulcerative Colitis Patients: An Update","volume":"22","author":"Scaldaferri","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_28","first-page":"372","article-title":"Preventive Effects of Escherichia Coli Strain Nissle 1917 on Acute and Chronic Intestinal Inflammation in Two Different Murine Models of Colitis","volume":"11","author":"Schultz","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining Remission of Ulcerative Colitis with the Probiotic Escherichia Coli Nissle 1917 Is as Effective as with Standard Mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1046\/j.1365-2036.1997.00225.x","article-title":"Double-Blind Comparison of an Oral Escherichia Coli Preparation and Mesalazine in Maintaining Remission of Ulcerative Colitis","volume":"11","author":"Kruis","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(98)06343-0","article-title":"Non-Pathogenic Escherichia coli versus Mesalazine for the Treatment of Ulcerative Colitis: A Randomised Trial","volume":"354","author":"Rembacken","year":"1999","journal-title":"Lancet Lond. Engl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.15403\/jgld.2014.1121.244.ecn","article-title":"Escherichia Coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-Analysis","volume":"24","author":"Losurdo","year":"2015","journal-title":"J. Gastrointest. Liver Dis. JGLD"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"680","DOI":"10.5152\/tjg.2019.18426","article-title":"Effects of Pentasa-Combined Probiotics on the Microflora Structure and Prognosis of Patients with Inflammatory Bowel Disease","volume":"30","author":"Fan","year":"2019","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.3748\/wjg.v24.i37.4254","article-title":"VSL#3 Can Prevent Ulcerative Colitis-Associated Carcinogenesis in Mice","volume":"24","author":"Wang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/978-1-4939-3603-8_26","article-title":"AOM\/DSS Model of Colitis-Associated Cancer","volume":"1422","author":"Parang","year":"2016","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1097\/MIB.0000000000000084","article-title":"Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis: A Meta-Analysis","volume":"20","author":"Mardini","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dang, X., Xu, M., Liu, D., Zhou, D., and Yang, W. (2020). Assessing the Efficacy and Safety of Fecal Microbiota Transplantation and Probiotic VSL#3 for Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228846"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert Consensus Document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) Consensus Statement on the Definition and Scope of Prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/gut.2010.232025","article-title":"Randomised, Double-Blind, Placebo-Controlled Trial of Fructo-Oligosaccharides in Active Crohn\u2019s Disease","volume":"60","author":"Benjamin","year":"2011","journal-title":"Gut"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hafer, A., Kr\u00e4mer, S., Duncker, S., Kr\u00fcger, M., Manns, M.P., and Bischoff, S.C. (2007). Effect of Oral Lactulose on Clinical and Immunohistochemical Parameters in Patients with Inflammatory Bowel Disease: A Pilot Study. BMC Gastroenterol., 7.","DOI":"10.1186\/1471-230X-7-36"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Limketkai, B.N., Godoy-Brewer, G., Shah, N.D., Maas, L., White, J., Parian, A.M., and Mullin, G.E. (2024). Prebiotics for Induction and Maintenance of Remission in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm. Bowel Dis., izae115.","DOI":"10.1093\/ibd\/izae115"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Gao, X., Xu, F., Li, T., Huang, P., Yu, L., Tian, F., Zhao, J., Chen, W., and Zhai, Q. (2024). CAZymes-Associated Method to Explore Glycans That Mitigate DSS-Induced Colitis via Targeting Bacteroides Cellulosilyticus. Int. J. Biol. Macromol., 258.","DOI":"10.1016\/j.ijbiomac.2023.128694"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zheng, J., Gong, S., and Han, J. (2023). Arabinogalactan Alleviates Lipopolysaccharide-Induced Intestinal Epithelial Barrier Damage through Adenosine Monophosphate-Activated Protein Kinase\/Silent Information Regulator 1\/Nuclear Factor Kappa-B Signaling Pathways in Caco-2 Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015337"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5114\/pg.2021.103666","article-title":"Guidelines for the management of patients with Crohn\u2019s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology","volume":"16","author":"Eder","year":"2021","journal-title":"Gastroenterol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/pg.2023.125882","article-title":"Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology","volume":"18","author":"Eder","year":"2023","journal-title":"Gastroenterol. Rev."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/13\/2092\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:08:04Z","timestamp":1760108884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/16\/13\/2092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,30]]},"references-count":45,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["nu16132092"],"URL":"https:\/\/doi.org\/10.3390\/nu16132092","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,30]]}}}